Visit RabiesWatch for more information on rabies exposures and the virus in the US.

Patient Profiles

The CDC's Advisory Committee on Immunization Practices recommends: "If anatomically feasible, the full dose of HRIG should be thoroughly infiltrated in the area around and into the wounds. Any remaining volume should be injected IM at a site from vaccine administration."1

Margaret-Ellen Williams*

Age: 20

Location: Westminster, Maryland

Incident: Margaret-Ellen, a college student, was on a walk with three friends in town. On a side street, they discovered a small, dirty, stray dog that they thought they might rescue and take to the dog shelter. When Margaret-Ellen leaned over to examine the dog, it snapped at her causing a wound on her nose and then ran away. The young woman immediately went to the local emergency room to have the bite taken care of.

Diagnosis: The doctor in the local emergency department confirmed that:

  • Margaret-Ellen had not been previously vaccinated for rabies
  • The dog could not be located

Treatment: The doctor thoroughly cleansed the small wound and infiltrated it with as much of the total dose of rabies immune globulin (HyperRAB® [rabies immune globulin (human)]) as possible . The total dose could not be infiltrated at the wound site, and the remainder of the total dose was given intramuscularly (IM) in the arm. The first dose of rabies vaccine was administered IM in the opposite arm.

Outcome: Thanks to the comprehensive treatment she received, Margaret-Ellen was able to return to her normal activities with friends at school.

Bats are the most common source of rabies exposures in the US; exposure to saliva from a bat, or other infected animal, through a mucous membrane can cause risk.1,2

The Hernandez Family

Rob and Tina and their 3 children*

Location: Pine Forest, Texas

Incident: Rob and Tina were awakened in the night by their youngest son saying there was a "bird" in the room that he shared with his older brother. When they investigated, they discovered a bat flying around the room while their older son slept. They opened a window and allowed the bat to escape. Their daughter was asleep in the adjacent room. There were no evident wounds or scratches. Tina related the incident to a neighbor, who urged the family to seek emergency care.

Diagnosis: When the family arrived at the emergency department, the attending physician determined that:

  • No family member had been previously vaccinated
  • The animal could not be located

Treatment: Even though the rabies exposure may not have resulted in a wound, exposure to animal's (particularly a bat's) saliva through a mucus membrane or open skin carries high risk. Therefore, the doctor administered a rabies vaccine and a dose of rabies immune globulin (HyperRAB) to each family member. Because there were no evident wound sites, the total dose of rabies immune globulin was administered IM in the deltoid or IM in the arm.3

Outcome: Thanks to the comprehensive treatment the family received, they returned to home, confident that their family was protected.

Indication and Usage

HYPERRAB® (rabies immune globulin [human]) is indicated for postexposure prophylaxis, along with rabies vaccine, for all persons suspected of exposure to rabies.

Limitations of Use 

Persons who have been previously immunized with rabies vaccine and have a confirmed adequate rabies antibody titer should receive only vaccine.

For unvaccinated persons, the combination of HYPERRAB and vaccine is recommended for both bite and nonbite exposures regardless of the time interval between exposure and initiation of postexposure prophylaxis.

Beyond 7 days (after the first vaccine dose), HYPERRAB is not indicated since an antibody response to vaccine is presumed to have occurred.

Important Safety Information

For infiltration and intramuscular use only.

Severe hypersensitivity reactions may occur with HYPERRAB. Patients with a history of prior systemic allergic reactions to human immunoglobulin preparations are at a greater risk of developing severe hypersensitivity and anaphylactic reactions. Have epinephrine available for treatment of acute allergic symptoms, should they occur.

HYPERRAB is made from human blood and may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

The most common adverse reactions in >5% of subjects during clinical trials were injection-site pain, headache, injection-site nodule, abdominal pain, diarrhea, flatulence, nasal congestion, and oropharyngeal pain.

Do not administer repeated doses of HYPERRAB once vaccine treatment has been initiated as this could prevent the full expression of active immunity expected from the rabies vaccine.

Other antibodies in the HYPERRAB preparation may interfere with the response to live vaccines such as measles, mumps, polio, or rubella. Defer immunization with live vaccines for 4 months after HYPERRAB administration.  

Please see full Prescribing Information for HYPERRAB.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.


  1. Manning SE, Rupprecht CE, Fishbein D, et al; Advisory Committee on Immunization Practices Centers for Disease Control and Prevention (CDC). Human rabies prevention—United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2008;57(RR-3):1-28.
  2. Centers for Disease Control and Prevention (CDC). Learning about bats and rabies. CDC website. Updated April 22, 2011. Accessed December 4, 2017.
  3. Centers for Disease Control and Prevention. How is rabies transmitted? Centers for Disease Control and Prevention website. Updated April 22, 2011. Accessed April 11, 2016.